熱門資訊> 正文

Corcept的卵巢癌治疗正在接受FDA审查

2025-09-10 20:51

Corcept Therapeutics (NASDAQ:CORT) said that the U.S. FDA will review its marketing application for relacorilant, its oral therapy, for the treatment of platinum-resistant ovarian cancer.
The agency has assigned a target action date of July 11, 2026.
Corcept’s application is based on positive data from its pivotal trials.

More on Corcept Therapeutics

Corcept's Q2 Demand Grows 60%, Penetrating Large Type 2 Diabetes Market Early
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Corcept anticipates relacorilant approval and projects $3B–$5B annual hypercortisolism revenue by 2028 as pharmacy capacity expands
Corcept Therapeutics GAAP EPS of $0.90 beats by $0.71, revenue of $194.4M misses by $4.99M

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。